Altimmune (NASDAQ:ALT) CEO Acquires $70,800.00 in Stock

Altimmune, Inc. (NASDAQ:ALT) CEO Jerome Benedict Durso purchased 20,000 shares of the stock in a transaction on Friday, March 6th. The stock was acquired at an average price of $3.54 per share, with a total value of $70,800.00. Following the completion of the acquisition, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at approximately $115,050. This represents a 160.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Jerome Benedict Durso also recently made the following trade(s):

• On Monday, December 22nd, Jerome Benedict Durso purchased 12,500 shares of Altimmune stock. The shares were acquired at an average cost of $4.13 per share, for a total transaction of $51,625.00.

Altimmune Trading Up 0.9%

NASDAQ:ALT opened at $3.54 on Monday. The company has a debt-to-equity ratio of 0.08, a current ratio of 17.18 and a quick ratio of 17.18. The business’s 50-day simple moving average is $4.48 and its 200-day simple moving average is $4.29. Altimmune, Inc. has a fifty-two week low of $2.90 and a fifty-two week high of $7.73. The stock has a market capitalization of $399.43 million, a PE ratio of -3.50 and a beta of 0.13.

Altimmune (NASDAQ:ALT) last posted its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 54.03% and a negative net margin of 214,860.98%. Sell-side analysts expect that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on ALT shares. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Barclays initiated coverage on Altimmune in a report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 target price for the company. Wall Street Zen lowered Altimmune from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Finally, William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Thursday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $16.60.

Institutional Trading of Altimmune

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Arax Advisory Partners boosted its position in Altimmune by 99.7% during the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after purchasing an additional 4,076 shares during the last quarter. SBI Securities Co. Ltd. raised its stake in shares of Altimmune by 27.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after purchasing an additional 1,928 shares in the last quarter. Quadrature Capital Ltd bought a new stake in shares of Altimmune during the 4th quarter worth approximately $36,000. Victory Capital Management Inc. acquired a new stake in shares of Altimmune in the 3rd quarter valued at approximately $38,000. Finally, CreativeOne Wealth LLC bought a new position in shares of Altimmune in the fourth quarter valued at $38,000. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.